Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01478321 · ClinicalTrials.gov registry record · Phase 2
Efficacy of Hypofractionated XRT w/Bev. + Temozolomide for Recurrent Gliomas
A Phase 2 study, sponsored by Northwestern University.
- Terminated
- Registry status
- Phase 2
- Development phase
- 54
- Enrollment target
NCT01478321 is a Phase 2 study that was terminated before completion, run by Northwestern University. The registered enrollment target is 54 participants.
The verdict
NCT01478321, a Phase 2 study, was terminated before completion, sponsored by Northwestern University.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 54 participants
- Enrollment target
Study Summary
This phase II trial studies how well giving hypofractionated radiation therapy together with temozolomide and bevacizumab works in treating patients with high-grade glioblastoma multiforme or anaplastic glioma. Specialized radiation therapy, such as hypofractionated radiation therapy, that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Giving hypofractionated radiation therapy together with temozolomide and bevacizumab may kill more tumor cells.
Interventions
- DRUG Temozolomide
- OTHER questionnaire administration
- BIOLOGICAL bevacizumab
- RADIATION hypofractionated radiation therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 54 participants |
| Start Date | 2011-12-14 |
| Est. Completion | 2018-09-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01478321
The ClinicalTrials.gov registry entry for NCT01478321 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 54 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Northwestern University, which has 1,209 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Temozolomide is the first listed.
NCT01478321 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01478321 about?
NCT01478321 is a clinical study titled "Efficacy of Hypofractionated XRT w/Bev. + Temozolomide for Recurrent Gliomas". This phase II trial studies how well giving hypofractionated radiation therapy together with temozolomide and bevacizumab works in treating patients with high-grade glioblastoma multiforme or anaplastic glioma. Specialized radiation therapy, such as hypofractionated radiation therapy, that delivers ...
What is the current status of trial NCT01478321?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 54 participants. The study started on 2011-12-14. Estimated completion is 2018-09-12.
What interventions are being tested in trial NCT01478321?
The interventions under investigation include: Temozolomide (DRUG), questionnaire administration (OTHER), bevacizumab (BIOLOGICAL), hypofractionated radiation therapy (RADIATION).
Who is sponsoring clinical trial NCT01478321?
This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.